Long Noncoding RNA CCAT2 as a Potential Novel Biomarker to Predict the Clinical Outcome of Cancer Patients: A Meta-Analysis

Abstract

Background: Colon Cancer-Associated Transcript 2 (CCAT2) has been demonstrated associated with clinical outcomes in various tumors. However, the results from each study were unfortunately insufficient and not completely consistent. Therefore, we conduct a systematic meta-analysis to evaluate the value for a feasible biomarker for metastasis and prognosis.Methods: A meta-analysis was performed using data obtained through a systematic search of PubMed, EMBASE, Cochrane Library, China National Knowledge Infrastructure, Wanfang database and VIP database. The pooled odds ratio (OR) and hazard ratio (HR) with 95% Confidence interval (CI ) using random-effect were used to identify the relationship of CCAT2 with clinical outcome of cancer patients. Subgroup analysis and sensitivity analysis were performed.Results: A total of 867 patients from eight studies were finally included. Patients with high CCAT2 expression underwent an increased risk of lymph node metastasis (LNM) (OR=3.09, 95% CI: 1.53-6.26) and distant metastasis (DM) (OR=7.70, 95% CI: 3.26-18.17). CCAT2 was also significantly correlated with overall survival (OS) (HR=2.19, 95%CI: 1.70-2.82) and progression-free survival (PFS) (HR=2.59, 95% CI: 1.78-3.76). Moderate heterogeneity was observed in meta-analysis for LNM. However, the results remained robust in multiple sensitivity analyses.Conclusions: High expression of CCAT2 was linked with poor clinical outcome. CCAT2 can serve as a potential molecular marker for prognosis in different types of cancers.

Long non-coding RNA colon cancer-associated transcript 2: role and function in human cancers

“…Additionally, the elevated CCAT2 expression was also considerably correlated with LNM, DM, and tumor stage. Furthermore, results of several other meta-analyzes on CCAT2 [37–40] have revealed similar results. Therefore, high CCAT2 expression is a predictor of unfavorable DM, LNM, PFS, OS, and later tumor stages [Supplementary Figures 1–8, http://links.lww.com/CM9/B423].…”

Long non-coding RNAs as novel prognostic biomarkers for breast cancer in Egyptian women

“…In our study, low SNCG expression was significantly associated with reduced OS in MBC patients (p = 0.049, log-rank), while Wu et al reported that SNCG-positive patients showed a significantly poorer prognosis than SNCG-negative patients 32 . Low CCAT2 expression was significantly associated with decreased OS (p = 0.023, log-rank) in NMBC patients, while Tan et al found that CCAT2 was significantly correlated with OS and progression-free survival 54 .…”

Prognostic and clinicopathologic significance of long non-coding RNA opa-interacting protein 5-antisense RNA 1 in multiple human cancers

“…Recently, lncRNA has been shown to participate in the initiation, development and progression in different cancers and has raised researchers' interest in last consecutive years. Among them, some lncRNAs including CCAT2, SNHG16, and GIHCG, could function as tumor oncogenes and facilitate tumorigenesis or tumor progression [40][41][42], while other lncRNAs such as BLACAT1, NORAD, NEF are well established as tumor suppressors [43][44][45].…”